secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2025-02-07T23:59:59+00:00
Accession:  0001837607-25-000010
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma receives NYSE American delisting notice over stockholder deficit of $32.1M
--------------------------------------------------------------------------------

- Received notice on Feb 3, 2025 for non-compliance with Section 1003(a)(i) requiring $2M+ stockholders' equity.
- Reported stockholders' deficit of $32.1M as of Sept 30, 2024 and losses in two of the three most recent fiscal years.
- Must submit a compliance plan by March 5, 2025; has until Aug 3, 2026 to regain compliance.
- If plan not accepted or fails, delisting proceedings will commence; shares will trade with ".BC" designation.
- No immediate impact on listing or business operations; company intends to submit a plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000010/0001837607-25-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000010/aeon-20250203x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-25-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer